Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis

Abstract Patients with long-standing ulcerative colitis (UC) have an increased colorectal cancer (CRC) risk. In this pilot study we evaluated the effect of Eicosapentaenoic acid as free fatty acid (EPA-FFA) supplementation on mucosal disease activity, colonic differentiation markers and microbiota c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Anna Prossomariti, Eleonora Scaioli, Giulia Piazzi, Chiara Fazio, Matteo Bellanova, Elena Biagi, Marco Candela, Patrizia Brigidi, Clarissa Consolandi, Tiziana Balbi, Pasquale Chieco, Alessandra Munarini, Milena Pariali, Manuela Minguzzi, Franco Bazzoli, Andrea Belluzzi, Luigi Ricciardiello
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Q
Acceso en línea:https://doaj.org/article/4e3561bd67f740f69cdf357ffa89ab3f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:4e3561bd67f740f69cdf357ffa89ab3f
record_format dspace
spelling oai:doaj.org-article:4e3561bd67f740f69cdf357ffa89ab3f2021-12-02T15:05:57ZShort-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis10.1038/s41598-017-07992-12045-2322https://doaj.org/article/4e3561bd67f740f69cdf357ffa89ab3f2017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-07992-1https://doaj.org/toc/2045-2322Abstract Patients with long-standing ulcerative colitis (UC) have an increased colorectal cancer (CRC) risk. In this pilot study we evaluated the effect of Eicosapentaenoic acid as free fatty acid (EPA-FFA) supplementation on mucosal disease activity, colonic differentiation markers and microbiota composition in UC patients. Twenty long-standing UC patients in stable clinical remission and with fecal calprotectin (FC) > 150 µg/g were enrolled (T0) and supplemented with EPA-FFA 2 g/daily for 90 days (T3). Endoscopic and histologic disease activities were measured by Mayo and Geboes scores, respectively. HES1, KLF4, STAT3, IL-10 and SOCS3 levels were determined using western blotting and qRT-PCR, while phospho-STAT3 levels were assessed by western blotting. Goblet cells were stained by Alcian blue. Microbiota analyses were performed on both fecal and colonic samples. Nineteen patients completed the study; seventeen (89.5%) were compliant. EPA-FFA treatment reduced FC levels at T3. Patients with FC > 150 µg/g at T3 (n = 2) were assumed as non-responders. EPA-FFA improved endoscopic and histological inflammation and induced IL-10, SOCS3, HES1 and KLF4 in compliant and responder patients. Importantly, long-term UC-driven microbiota composition was partially redressed by EPA-FFA. In conclusion, EPA-FFA supplementation reduced mucosal inflammation, promoted goblet cells differentiation and modulated intestinal microbiota composition in long-standing UC patients.Anna ProssomaritiEleonora ScaioliGiulia PiazziChiara FazioMatteo BellanovaElena BiagiMarco CandelaPatrizia BrigidiClarissa ConsolandiTiziana BalbiPasquale ChiecoAlessandra MunariniMilena ParialiManuela MinguzziFranco BazzoliAndrea BelluzziLuigi RicciardielloNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Anna Prossomariti
Eleonora Scaioli
Giulia Piazzi
Chiara Fazio
Matteo Bellanova
Elena Biagi
Marco Candela
Patrizia Brigidi
Clarissa Consolandi
Tiziana Balbi
Pasquale Chieco
Alessandra Munarini
Milena Pariali
Manuela Minguzzi
Franco Bazzoli
Andrea Belluzzi
Luigi Ricciardiello
Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis
description Abstract Patients with long-standing ulcerative colitis (UC) have an increased colorectal cancer (CRC) risk. In this pilot study we evaluated the effect of Eicosapentaenoic acid as free fatty acid (EPA-FFA) supplementation on mucosal disease activity, colonic differentiation markers and microbiota composition in UC patients. Twenty long-standing UC patients in stable clinical remission and with fecal calprotectin (FC) > 150 µg/g were enrolled (T0) and supplemented with EPA-FFA 2 g/daily for 90 days (T3). Endoscopic and histologic disease activities were measured by Mayo and Geboes scores, respectively. HES1, KLF4, STAT3, IL-10 and SOCS3 levels were determined using western blotting and qRT-PCR, while phospho-STAT3 levels were assessed by western blotting. Goblet cells were stained by Alcian blue. Microbiota analyses were performed on both fecal and colonic samples. Nineteen patients completed the study; seventeen (89.5%) were compliant. EPA-FFA treatment reduced FC levels at T3. Patients with FC > 150 µg/g at T3 (n = 2) were assumed as non-responders. EPA-FFA improved endoscopic and histological inflammation and induced IL-10, SOCS3, HES1 and KLF4 in compliant and responder patients. Importantly, long-term UC-driven microbiota composition was partially redressed by EPA-FFA. In conclusion, EPA-FFA supplementation reduced mucosal inflammation, promoted goblet cells differentiation and modulated intestinal microbiota composition in long-standing UC patients.
format article
author Anna Prossomariti
Eleonora Scaioli
Giulia Piazzi
Chiara Fazio
Matteo Bellanova
Elena Biagi
Marco Candela
Patrizia Brigidi
Clarissa Consolandi
Tiziana Balbi
Pasquale Chieco
Alessandra Munarini
Milena Pariali
Manuela Minguzzi
Franco Bazzoli
Andrea Belluzzi
Luigi Ricciardiello
author_facet Anna Prossomariti
Eleonora Scaioli
Giulia Piazzi
Chiara Fazio
Matteo Bellanova
Elena Biagi
Marco Candela
Patrizia Brigidi
Clarissa Consolandi
Tiziana Balbi
Pasquale Chieco
Alessandra Munarini
Milena Pariali
Manuela Minguzzi
Franco Bazzoli
Andrea Belluzzi
Luigi Ricciardiello
author_sort Anna Prossomariti
title Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis
title_short Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis
title_full Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis
title_fullStr Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis
title_full_unstemmed Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis
title_sort short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis
publisher Nature Portfolio
publishDate 2017
url https://doaj.org/article/4e3561bd67f740f69cdf357ffa89ab3f
work_keys_str_mv AT annaprossomariti shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT eleonorascaioli shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT giuliapiazzi shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT chiarafazio shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT matteobellanova shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT elenabiagi shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT marcocandela shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT patriziabrigidi shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT clarissaconsolandi shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT tizianabalbi shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT pasqualechieco shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT alessandramunarini shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT milenapariali shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT manuelaminguzzi shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT francobazzoli shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT andreabelluzzi shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
AT luigiricciardiello shorttermtreatmentwitheicosapentaenoicacidimprovesinflammationandaffectscolonicdifferentiationmarkersandmicrobiotainpatientswithulcerativecolitis
_version_ 1718388642441854976